Consultant for conduction of Easter Europe and Central Asia Constituency governance review

Association Partnerships in Health, Sarajevo, Bosnia-Herzegovina

Skill Required:, Monitoring and EvaluationResearch and Analysis
Preferred Experience: 
3 to 10 Years
Email for CV Submission: 
Closing Date for Applications: 
25th January, 2015


Job Description

Terms of Reference (TOR) for a Short term assignment

 

Position: Consultant for conduction of governance review

 

  1. Background

The Eastern Europe and Central Asia Constituency (EECA Constituency) is one of the 10 constituencies representing implementing countries at the Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria (TGF).  The EECA Constituency represents 22 countries of Eastern Europe and Central Asia region.  As a representative of the countries of the region, the EECA Constituency is one of the 7 “government” constituencies within the Implementers block (IB), although the EECA delegates come from both sectors; the government and the civil society. 

The EECA region is home to the highest rates of multidrug-resistant TB (MDR-TB) in the world and accounts for nearly 20 percent of the global burden[1]. The EECA countries continue to represent hot spots for MDR-TB, with nearly one third of new and two thirds of previously treated TB cases affected by MDR-TB in some settings. In several of these countries, 9–32% of new cases have MDR-TB and more than 50% of previously treated cases have MDR-TB. The European region is not on track to halve 1990 levels of mortality by 2015 compare to other countries in the region. Improvement in treatment outcomes is needed in the Region, where the treatment success rate in 2010 was 74% and 67% for new cases and new smear positive cases respectively. TB is among the main causes of death among people living with HIV in EECA[2].

An estimated 1.4 million (range 1.1m – 1.8) adults and children are living with HIV in EECA region; more than 1% of adults in the region are living with HIV. The number of people dying from AIDS-related causes in the region experienced significant increase (21%) from 2005 to 2011. The HIV epidemic continues to be concentrated among PWID: the population most severely affected by HIV in the region. Of the estimated 15.9 million (range 11m – 21.2m) PWID worldwide, 3.7 million – nearly a quarter – live in EECA. Based on national-level estimates, the largest PWID populations are reported in Russia (1.8 million) and Ukraine (296,000). An estimated 25% PWID in the region – almost 1 million - are living with HIV.[3]

The Eastern Europe and Central Asian region is experiencing concurrent HIV and TB epidemics significantly and disproportionately affecting people who use drugs. Prevalence of injection drug use nears or exceeds 1% in the majority of countries in the region[4]. While much of the world is seeing declines in new HIV infections, the HIV epidemic in EECA continues to expand[5]. In many countries in the region, HIV infection rates among PWID are many times higher than the prevalence rate in the general population: for example, in Ukraine 21.5% of PWID are living with HIV versus 0.8% of the general population[6]; in Belarus, more than 15% among drug injectors versus 0.4% in the general population; in Estonia, more than 50% in drug injectors versus 1.3% in the general population; and in Tajikistan, more than 15% among drug injectors versus 0.3% in the general population[7].

Increasing rates of TB/HIV co-infection and limited access to treatment for both diseases contribute to the increased vulnerability of PWID in the region. The EECA is home to the highest rates of multidrug-resistant TB (MDR-TB) in the world and accounts for nearly 20% of the global burden. TB is among the main causes of death among people living with HIV in EECA.[8],[9] Viral hepatitis is considerably more widespread than HIV among PWID in EECA, with five countries in the region reporting hepatitis C (HCV) prevalence higher than 70% among this population.

The members of the EECA Constituency are prominent professionals, managers and leaders in the response to the HIV and TB in their respective countries.  The capacities of the EECA Constituency members are not limited to the EECA region only; some of them have taken a part of many international initiatives as well.  A vast majority of the Constituency members are the CCM members and have been or currently occupy leadership positions in the CCMs; some of them perform different functions in the CCM Secretariats etc. However, each EECA Constituency member has to have a mandatory authorisation from the CCM/Ministry of Health/Ministry of Foreign Affairs of the respective country to represent the country at the EECA Constituency.  The majority of the members have been or are right now actively involved in the implementation of the GFATM funded programmes and projects, either in the role of the PR or SR.   

  

 

 

 

 

 

  1. Objectives

The objectives of the governance review are:

  • To understand how well the governance model and practice is adapted to the organisational realities and ambitions of the Eastern Europe and Central Asia Constituency
  • To understand how effective the governance model and practice is compared to best practice standards within the sector
  • To identify lessons learnt and come up with recommendations for further refining and improving the governance model and practice

 

  1. Tasks and Responsibilities

The consultant will be expected to:

  • Familiarise themselves with background documentation;
  • Conduct interviews with country representatives within the EECA constituency;
  • Recommend improvement modalities and present minimum 3 options for each improvement area identified;
  • Present recommendations to the Technical Support Office via Skype communication and draft report;
  • Uptake received inputs in the final report.

The EECA Constituency Technical Support Office will supply all relevant and requested documentation, as well as contact details of members and other required contact people.

 

  1. Time frame and duration

The total duration of the consultancy will be 35 days. Provision of the service will begin after the signature of contract between the Consultant and Partnerships in Health. The start date is planned for 5 February 2015.

The whole process should be finalized before 11 March 2015.

 

  1. Deliverables
  2.  

Deliverables include:

  • First Draft of the governance review report based on the outputs mentioned above for feedback from the project by 4 March 2015;
  • Final consultancy report by 11 March 2015.
  1. Requirements for Submission of Brief Proposals/Concept Note

The individual consultants will be required to submit their CVs along with a cover letter and a 3-4 pages concept note covering relevant experience approach/proposed methodology and financial proposal for the review.

 

  1. Qualification and Experience
  • University degree, Master or PhD in the field of social sciences,
  • At least 3 years of experience in the field of governance review,
  • Proven experience in consultancy to International organizations, government agencies, and civil society organizations,
  • Knowledge of political and administrative issues of the Region and about GFTAM projects (Concept Notes, stages of implementation) from the member states,
  • Extensive understanding of the Global Fund and its processes and policies,
  • Analytical and conceptual ability,
  • Excellent written and oral communication skills in English language,
  • Knowledge of Russian language.

 

 

Applications not including all of the above information will not be reviewed. Only short listed candidates will be contacted.

 

All applications should be sent to Association Partnerships in Health – Technical Support Office at tso@aph.ba with the subject line: “Consultant for Governance Review”. Applications should be submitted no later than 2 February 2015.

 


[1] World Health Organization: Europe (2011) Roadmap to prevent and combat drug-resistant tuberculosis: The Consolidated Action Plan to Prevent and Combat Multidrug- and Extensively Drug-Resistant Tuberculosis in the WHO European Region, 2011-2015 Copenhagen

[2] World Health Organization: Europe (2012) The Way Forward: scaling up action to prevent and control major communicable diseases Copenhagen

[3] HRI, The Global State of Harm Reduction, 2012

[4] Mathers B et al. for the Reference Group to the UN on HIV and Injecting Drug Use (2008) Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review, Lancet, 372( 9651):1733–1745.

[5] UNAIDS (2012) UNAIDS Report on the Global AIDS Epidemic. Geneva

[6] National Council to Fight TB and HIV/AIDS Ukraine Harmonised AIDS Response Report (2012) Kyiv

[7] UNAIDS (2012) Regional Fact Sheet: Eastern Europe and Central Asia Geneva

[8] WHO Europe, Roadmap to prevent and combat drug-resistant tuberculosis: The Consolidated Action Plan to Prevent and Combat Multidrug- and Extensively Drug-Resistant Tuberculosis in the WHO European Region, 2011, Copenhagen

[9] WHO Europe, The Way Forward: scaling up action to prevent and control major communicable diseases, 2012, Copenhagen

 


Recommend your friend

Copyrights 2017. All rights reserved | Technology Partner: Indev Consultancy Pvt. Ltd